Results for Chronic Pancreatitis

1 - 7 of 7

Dr. Stallings is working on intervention trials involving three chronic diseases with nutrition-related abnormalities resulting in meaningful adverse outcomes: cystic fibrosis (new drugs), sickle cell disease (vitamin A) and chronic pancreatitis (enzyme replacement drug).

E-mail:

stallingsv [at] chop.edu

Committed to Pediatric Palliative Care: Q&A With Chris Feudtner, MD, PhD, MPH

Published on

May 5, 2023

in Cornerstone Blog

Committed to Pediatric Palliative Care: Q&A With Chris Feudtner, MD, PhD, MPH

The American Pediatric Society honored Dr. Feudtner for his contributions to pediatric sciences.

CHOP Research Institute Scientific Symposium: Harnessing the Immune Response

Published on

Jun 2, 2022

in Cornerstone Blog

Scientific Symposium 2022: Harnessing the Immune Response

CHOP and Penn researchers discussed the latest findings about the mechanisms of immunity at the CHOP Research Institute 2022 Scientific Symposium.

FDA Approves Personalized Cellular Therapy for Advanced Leukemia Developed by University of Pennsylvania and Children’s Hospital of Philadelphia

Published on

Aug 29, 2017

in Press Releases

Pioneering CAR T-cell Studies Led to First-ever Cancer Cell and Gene Therapy Approval

Investigating Breakthrough Cystic Fibrosis Drug's Effect on Weight

Published on

Apr 16, 2014

in Cornerstone Blog

A new project at The Children’s Hospital of Philadephia seeks to gain a clearer idea of what effect the novel cystic fibrosis drug ivacaftor has on energy balance and weight gain.

Pediatric Study of Acute Recurrent and Chronic Pancreatitis

The goals of this research study are to learn more about acute recurrent and chronic pancreatitis in order to better understand the disease in the hopes of enhancing future treatment options.

Cystic Fibrosis-Related Diabetes Research Program

Focusing on the underpinnings of progressive insulin secretion defects and worsening glucose tolerance in children and adults with cystic fibrosis, and examining the links between hyperglycemia and insulin deficiency and cystic fibrosis-related outcomes.